SequelSEC

Immix Biopharma, Inc. IMMX

Pharmaceutical Preparations · CIK 0001873835 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$29.96M
Fiscal year ended 2025-12-31
Free cash flow
-$24.66M
Fiscal year ended 2025-12-31

Immix Biopharma, Inc. (IMMX) reported net income of -$29.40M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Immix Biopharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Immix Biopharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$29.96M-$22.67M-$16.14M-$8.22M-$1.35M-$453.85K
Net income-$29.40M-$21.61M-$15.43M-$8.23M-$24.38M-$1.15M
Research & development$16.26M$11.29M$8.74M$4.20M$126.53K$248.15K
Weighted-average diluted sharesshares 32.97Mshares 28.29Mshares 17.34Mshares 13.89MUnavailableUnavailable
Pretax income-$29.40M-$21.66M-$15.57M-$8.22M-$24.38M-$1.13M
Income tax expense$37.72K$41.04K$26.42K$10.27K$6.01K$17.55K
Diluted EPS$-0.89$-0.76$-0.89$-0.59UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$13.70M$11.38M$7.41M$4.02M$1.23M$205.70K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Immix Biopharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$93.93M$17.68M$17.51M$13.44M$17.64M$391.09K
Total assets$104.84M$22.95M$19.93M$14.91M$18.19M$539.60K
Current assets$101.24M$20.20M$19.79M$14.90M$18.19M$532.24K
Total liabilities$11.04M$9.70M$3.72M$1.75M$202.04K$5.27M
Current liabilities$10.11M$8.69M$3.72M$1.27M$202.04K$5.27M
Total equity incl. NCI$93.80M$13.25M$16.20M$13.16M$17.99M-$4.73M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$5.44M$5.39M$1.43M$143.07KUnavailableUnavailable

Cash flow

Immix Biopharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$23.93M-$14.60M-$11.37M-$7.41M-$1.59M-$404.69K
Capital expenditures$732.92K$1.18M$52.09KUnavailable$802Unavailable
Investing cash flow-$7.21M-$1.18M-$52.09KUnavailable-$802Unavailable
Financing cash flow$107.39M$15.95M$15.46M$3.23M$18.85MUnavailable
Net change in cash$76.25M$172.16K$4.07M-$4.21M$17.25M-$342.93K
Stock-based compensation$2.44M$3.02M$2.57M$624.07K$218.98KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable$99.96KUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Immix Biopharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$24.66M-$15.77M-$11.42MUnavailable-$1.59MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio10.01x2.33x5.32x11.70x90.01x0.10x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IMMX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K/A · Filed 2026-03-27View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.